Cutting edge

Oral type I IFN-τ promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate

Jeanne M. Soos, Olaf Stüve, Sawsan Youssef, Manuel Bravo, Howard M. Johnson, Howard L. Weiner, Scott S. Zamvil

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

IFN-τ, a novel type I IFN that possesses immunomodulatory properties, lacks toxicity normally associated with other type I IFNs. We examined the effects of oral IFN-τ alone and in combination with oral glatiramer acetate in experimental allergic encephalomyelitis (EAE). By comparison of oral administration of IFN-α, -β, and -τ to myelin basic protein-specific TCR-transgenic mice, we demonstrate these type I IFNs promote secretion of the Th2 cytokine IL-10 with similar efficiency. Whereas IFN-α and -β induced IFN-γ secretion, a Th1 cytokine, IFN-τ did not. Oral IFN-τ alone suppressed EAE. When suboptimal doses were administered orally in combination to wild-type mice, IFN-τ and glatiramer acetate had a synergistic beneficial effect in suppression of EAE. This combination was associated with TGF-β secretion and enhanced IL-10 production. Thus, IFN-τ is a potential candidate for use as a single agent or in combination therapy for multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)2231-2235
Number of pages5
JournalJournal of Immunology
Volume169
Issue number5
StatePublished - Sep 1 2002

Fingerprint

Encephalomyelitis
Autoimmune Experimental Encephalomyelitis
Interleukin-10
Cytokines
Myelin Basic Protein
Transgenic Mice
Multiple Sclerosis
Oral Administration
Glatiramer Acetate
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Soos, J. M., Stüve, O., Youssef, S., Bravo, M., Johnson, H. M., Weiner, H. L., & Zamvil, S. S. (2002). Cutting edge: Oral type I IFN-τ promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. Journal of Immunology, 169(5), 2231-2235.

Cutting edge : Oral type I IFN-τ promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. / Soos, Jeanne M.; Stüve, Olaf; Youssef, Sawsan; Bravo, Manuel; Johnson, Howard M.; Weiner, Howard L.; Zamvil, Scott S.

In: Journal of Immunology, Vol. 169, No. 5, 01.09.2002, p. 2231-2235.

Research output: Contribution to journalArticle

Soos, JM, Stüve, O, Youssef, S, Bravo, M, Johnson, HM, Weiner, HL & Zamvil, SS 2002, 'Cutting edge: Oral type I IFN-τ promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate', Journal of Immunology, vol. 169, no. 5, pp. 2231-2235.
Soos, Jeanne M. ; Stüve, Olaf ; Youssef, Sawsan ; Bravo, Manuel ; Johnson, Howard M. ; Weiner, Howard L. ; Zamvil, Scott S. / Cutting edge : Oral type I IFN-τ promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. In: Journal of Immunology. 2002 ; Vol. 169, No. 5. pp. 2231-2235.
@article{12b0b3271e254cc8b2584f0da4c146e1,
title = "Cutting edge: Oral type I IFN-τ promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate",
abstract = "IFN-τ, a novel type I IFN that possesses immunomodulatory properties, lacks toxicity normally associated with other type I IFNs. We examined the effects of oral IFN-τ alone and in combination with oral glatiramer acetate in experimental allergic encephalomyelitis (EAE). By comparison of oral administration of IFN-α, -β, and -τ to myelin basic protein-specific TCR-transgenic mice, we demonstrate these type I IFNs promote secretion of the Th2 cytokine IL-10 with similar efficiency. Whereas IFN-α and -β induced IFN-γ secretion, a Th1 cytokine, IFN-τ did not. Oral IFN-τ alone suppressed EAE. When suboptimal doses were administered orally in combination to wild-type mice, IFN-τ and glatiramer acetate had a synergistic beneficial effect in suppression of EAE. This combination was associated with TGF-β secretion and enhanced IL-10 production. Thus, IFN-τ is a potential candidate for use as a single agent or in combination therapy for multiple sclerosis.",
author = "Soos, {Jeanne M.} and Olaf St{\"u}ve and Sawsan Youssef and Manuel Bravo and Johnson, {Howard M.} and Weiner, {Howard L.} and Zamvil, {Scott S.}",
year = "2002",
month = "9",
day = "1",
language = "English (US)",
volume = "169",
pages = "2231--2235",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Cutting edge

T2 - Oral type I IFN-τ promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate

AU - Soos, Jeanne M.

AU - Stüve, Olaf

AU - Youssef, Sawsan

AU - Bravo, Manuel

AU - Johnson, Howard M.

AU - Weiner, Howard L.

AU - Zamvil, Scott S.

PY - 2002/9/1

Y1 - 2002/9/1

N2 - IFN-τ, a novel type I IFN that possesses immunomodulatory properties, lacks toxicity normally associated with other type I IFNs. We examined the effects of oral IFN-τ alone and in combination with oral glatiramer acetate in experimental allergic encephalomyelitis (EAE). By comparison of oral administration of IFN-α, -β, and -τ to myelin basic protein-specific TCR-transgenic mice, we demonstrate these type I IFNs promote secretion of the Th2 cytokine IL-10 with similar efficiency. Whereas IFN-α and -β induced IFN-γ secretion, a Th1 cytokine, IFN-τ did not. Oral IFN-τ alone suppressed EAE. When suboptimal doses were administered orally in combination to wild-type mice, IFN-τ and glatiramer acetate had a synergistic beneficial effect in suppression of EAE. This combination was associated with TGF-β secretion and enhanced IL-10 production. Thus, IFN-τ is a potential candidate for use as a single agent or in combination therapy for multiple sclerosis.

AB - IFN-τ, a novel type I IFN that possesses immunomodulatory properties, lacks toxicity normally associated with other type I IFNs. We examined the effects of oral IFN-τ alone and in combination with oral glatiramer acetate in experimental allergic encephalomyelitis (EAE). By comparison of oral administration of IFN-α, -β, and -τ to myelin basic protein-specific TCR-transgenic mice, we demonstrate these type I IFNs promote secretion of the Th2 cytokine IL-10 with similar efficiency. Whereas IFN-α and -β induced IFN-γ secretion, a Th1 cytokine, IFN-τ did not. Oral IFN-τ alone suppressed EAE. When suboptimal doses were administered orally in combination to wild-type mice, IFN-τ and glatiramer acetate had a synergistic beneficial effect in suppression of EAE. This combination was associated with TGF-β secretion and enhanced IL-10 production. Thus, IFN-τ is a potential candidate for use as a single agent or in combination therapy for multiple sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=0036721792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036721792&partnerID=8YFLogxK

M3 - Article

VL - 169

SP - 2231

EP - 2235

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -